Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
38 studies found for:    " August 25, 2010":" September 24, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study
Conditions: Hiv Infection;   Lung Cancer
Intervention: Radiation: Low dose computed tomography (CT)
22 Recruiting Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort
Conditions: HIV;   AIDS
Intervention:
23 Unknown  Study of Recently HIV Infected Men and Transmission Behaviors
Condition: HIV
Intervention:
24 Terminated A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: YASMIN;   Drug: GSK2248761;   Other: Placebo
25 Completed ZIAGEN® Post-marketing Surveillance
Condition: Infection, Human Immunodeficiency Virus I
Intervention: Drug: ZIAGEN®
26 Completed GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: GSK1349572;   Drug: Fosamprenavir;   Drug: Ritonavir
27 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Etravirine
28 Completed
Has Results
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
Conditions: HIV;   Cancer
Interventions: Biological: Fluzone High Dose Vaccine;   Biological: Fluzone Standard Dose Vaccine
29 Completed A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 WBM Capsule;   Drug: GSK2248761 WBM Tablet Formulation 1;   Drug: GSK2248761 WBM Tablet Formulation 2;   Drug: GSK2248761 WBM Tablet Formulation 3;   Drug: GSK2248761 WBM Tablet
30 Withdrawn Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth
Conditions: Chlamydia;   Gonorrhea;   HIV
Interventions: Behavioral: HIV testing;   Behavioral: STI/HIV-T;   Behavioral: STI/HIV-Plus
31 Completed Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure
Conditions: HIV;   AIDS;   Lopinavir;   Treatment Failure
Interventions: Drug: Ritonavir-boosted lopinavir;   Drug: optimized background regimens (OBRs)
32 Unknown  Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.
Condition: AIDS
Intervention: Drug: INH RIF Rifb PZA EMB AZT 3TC D4T EFV
33 Active, not recruiting Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Conditions: AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   Grade 3b Follicular Lymphoma;   HIV Infection;   Plasmablastic Lymphoma;   Primary Effusion Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate;   Drug: Vorinostat
34 Completed Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment
Condition: Male Circumcision
Intervention: Device: Shang Ring
35 Active, not recruiting Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Conditions: Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
36 Completed
Has Results
Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Conditions: Genital Warts;   Human Papilloma Virus
Intervention: Procedure: Medical / Surgical Treatment
37 Completed Comparison of the Shang Ring With Conventional Surgical Methods
Condition: Circumcision, Male
Interventions: Device: Shang Ring;   Procedure: Male circumcision
38 Recruiting EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)
Condition: Pregnancy Related
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-38) Next Page   
Study has passed its completion date and status has not been verified in more than two years.